Home / Going-concern warnings / Karyopharm Therapeutics Inc.
Filed 2025-08-11 路 Form 10-Q 路 Accession 0000950170-25-106238 nano
Price before filing: $3.94 (2025-08-08 close, split/dividend-adjusted)
Market cap at flag: $32.7M (2025-08-11) 路 Latest: $11.3M (2026-10-16)
| Window | KPTI | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +57.6% | +2.4% | +55.3% | 2025-09-10 |
| 90 days | +38.1% | +7.2% | +30.8% | 2025-11-10 |
| 180 days | +60.2% | +9.5% | +50.6% | 2026-02-09 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"Based on our current business plan and current capital resources, given the uncertainty regarding the availability of additional funding or other strategic alternatives and considering our debt service obligations, including our 3.00 % convertible senior notes maturing on October 15, 2025 (the "2025 Notes") with an aggregate principal amount of $ 24.5 million and a requirement of our Credit Agreement, as defined..."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-06-30)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.